Business
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuti...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, CanadaToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Programs will now reimburse eligible claims made for Trecondyv®, subject to satisfaction of any relevant conditions set out in the agreements.¹\"This important development is another reimbursement milestone following the successful completion of the pCPA negotiation process for Trecondyv®,\" said Richard Labelle, Medexus's Chief Operating Officer. \"It further demonstrates our commitment to seeking and quickly achieving public reimbursement of Trecondyv® across Canada, and is yet another important indicator of the prospects and potential of our treosulfan products - both Trecondyv® in the Canadian market and, in the US market, GRAFAPEX™ (treosulfan) for Injection, which was recently approved by the FDA.\"²The next step in the Trecondyv® public reimbursement process will be for other remaining government organizations to make their respective final decisions on public reimbursement for their regions or jurisdictions. Medexus is committed to continuing to work with these other participating provincial, territorial, and federal government organizations to make Trecondyv® available as soon as possible through public drug plans for the patients who need it.¹ Cancer Care Ontario, \"Drug Formulary\", available at www.cancercareontario.ca/en/search_2?field_type_of_contents=1&home_search=trecondyv (accessed February 3, 2025).² Medexus, news release: \"Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update\", available at https://www.medexus.com/en_US/news-media/press-releases/detail/176/medexus-announces-fda-approval-of-grafapex-treosulfan-for (accessed January 30, 2025) and on SEDAR+. See \"About GRAFAPEX™ (treosulfan) for Injection\" below.About Trecondyv® (treosulfan for injection)Treosulfan is part of a preparative regi...